uniQure (NASDAQ:QURE) Raised to Hold at Wall Street Zen

uniQure (NASDAQ:QURE) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

A number of other equities analysts have also recently commented on QURE. Sanford C. Bernstein cut shares of uniQure to a “market perform” rating in a research report on Tuesday, March 3rd. HC Wainwright reissued a “buy” rating and issued a $70.00 price objective on shares of uniQure in a research report on Tuesday, March 10th. Barclays cut their target price on shares of uniQure from $31.00 to $25.00 and set an “equal weight” rating for the company in a research note on Monday, March 23rd. Royal Bank Of Canada raised shares of uniQure from a “sector perform” rating to an “outperform” rating and lifted their target price for the stock from $11.00 to $35.00 in a report on Monday, March 9th. Finally, Stifel Nicolaus set a $14.00 price target on shares of uniQure in a report on Monday, March 2nd. Ten investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $42.75.

uniQure Stock Performance

QURE opened at $14.77 on Friday. uniQure has a 12-month low of $7.76 and a 12-month high of $71.50. The stock has a market cap of $923.57 million, a price-to-earnings ratio of -4.28 and a beta of 0.73. The business has a 50 day moving average of $19.91 and a 200-day moving average of $29.57. The company has a quick ratio of 10.43, a current ratio of 10.43 and a debt-to-equity ratio of 0.25.

uniQure (NASDAQ:QURE) last issued its earnings results on Tuesday, March 3rd. The biotechnology company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.93) by $0.37. uniQure had a negative return on equity of 174.03% and a negative net margin of 1,236.00%.The company had revenue of $5.57 million during the quarter, compared to the consensus estimate of $4.84 million. On average, equities research analysts expect that uniQure will post -3.75 earnings per share for the current year.

Insider Activity at uniQure

In other uniQure news, CFO Christian Klemt sold 12,000 shares of uniQure stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total value of $108,720.00. Following the completion of the sale, the chief financial officer owned 226,581 shares in the company, valued at $2,052,823.86. The trade was a 5.03% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jack Kaye sold 6,390 shares of the business’s stock in a transaction dated Friday, January 9th. The shares were sold at an average price of $27.28, for a total transaction of $174,319.20. Following the completion of the sale, the director directly owned 20,439 shares of the company’s stock, valued at $557,575.92. This represents a 23.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 81,399 shares of company stock valued at $1,527,645. 4.79% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in QURE. Avoro Capital Advisors LLC boosted its holdings in shares of uniQure by 38.4% in the 4th quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock valued at $147,170,000 after purchasing an additional 1,705,556 shares in the last quarter. Aberdeen Group plc raised its holdings in shares of uniQure by 25.1% during the 4th quarter. Aberdeen Group plc now owns 3,678,640 shares of the biotechnology company’s stock worth $88,030,000 after buying an additional 738,897 shares in the last quarter. State Street Corp lifted its position in shares of uniQure by 123.8% during the 4th quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock worth $77,319,000 after buying an additional 1,787,033 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in uniQure by 155.3% in the fourth quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock valued at $70,226,000 after buying an additional 1,785,275 shares in the last quarter. Finally, Franklin Resources Inc. boosted its stake in uniQure by 23.9% in the third quarter. Franklin Resources Inc. now owns 1,988,581 shares of the biotechnology company’s stock valued at $116,073,000 after buying an additional 383,066 shares in the last quarter. 78.83% of the stock is owned by institutional investors.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.